

# Susan Swindells

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/395616/publications.pdf>

Version: 2024-02-01

142  
papers

17,180  
citations

61984

43  
h-index

14208

128  
g-index

179  
all docs

179  
docs citations

179  
times ranked

14097  
citing authors

#	ARTICLE	IF	CITATIONS
1	Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. <i>Aids</i> , 2022, 36, 185-194.	2.2	38
2	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	5.8	4
3	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	9.1	28
4	High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2022, Publish Ahead of Print, .	2.0	7
5	Signatures of somatosensory cortical dysfunction in Alzheimer's disease and HIV-associated neurocognitive disorder. <i>Brain Communications</i> , 2022, 4, .	3.3	2
6	Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 801-809.	1.2	34
7	Long-acting drugs and formulations for the treatment and prevention of HIV infection. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106220.	2.5	63
8	Neighborhood Deprivation and Racial/Ethnic Disparities in Human Immunodeficiency Virus Viral Suppression: A Single-center, Cross-sectional Study in the United States Midwest. <i>Clinical Infectious Diseases</i> , 2021, 72, e642-e645.	5.8	15
9	Gray matter volumes discriminate cognitively impaired and unimpaired people with HIV. <i>NeuroImage: Clinical</i> , 2021, 31, 102775.	2.7	5
10	The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110090.	1.5	35
11	A Midwestern Academic HIV Clinic Operation during the COVID-19 Pandemic: Implementation Strategy and Preliminary Outcomes. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021, 20, 232595822110414.	1.5	9
12	Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. <i>BMC Infectious Diseases</i> , 2021, 21, 205.	2.9	6
13	Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. <i>BMC Health Services Research</i> , 2021, 21, 255.	2.2	16
14	Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1037-1045.	5.8	4
15	Reductions in Gray Matter Linked to Epigenetic HIV-Associated Accelerated Aging. <i>Cerebral Cortex</i> , 2021, 31, 3752-3763.	2.9	15
16	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). <i>Patient</i> , 2021, 14, 849-862.	2.7	28
17	Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 384, 1705-1718.	27.0	259
18	A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1327-1335.	5.6	18

#	ARTICLE	IF	CITATIONS
19	Cannabis use impacts pre-estimulus neural activity in the visual cortices of people with HIV. <i>Human Brain Mapping</i> , 2021, 42, 5446-5457.	3.6	7
20	Neuroinflammatory profiles regulated by the redox environment predicted cognitive dysfunction in people living with HIV: A cross-sectional study. <i>EBioMedicine</i> , 2021, 70, 103487.	6.1	8
21	Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 17-27.	1.5	10
22	Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	2
23	Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. <i>Clinical Infectious Diseases</i> , 2020, 70, 425-435.	5.8	18
24	Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 436-445.	5.8	2
25	Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 70, 698-703.	5.8	5
26	Epigenetic Markers of Aging Predict the Neural Oscillations Serving Selective Attention. <i>Cerebral Cortex</i> , 2020, 30, 1234-1243.	2.9	13
27	New opportunities in tuberculosis prevention: implications for people living with HIV. <i>Journal of the International AIDS Society</i> , 2020, 23, e25438.	3.0	20
28	Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 648-655.	3.0	20
29	Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans™ Association With Viral Suppression. <i>Clinical Infectious Diseases</i> , 2020, 71, 2572-2580.	5.8	8
30	Surprisingly Low Levels of Measles Immunity in Persons With HIV: A Seroprevalence Survey in a United States HIV Clinic. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa428.	0.9	6
31	Interactive effects of HIV and ageing on neural oscillations: independence from neuropsychological performance. <i>Brain Communications</i> , 2020, 2, fcaa015.	3.3	15
32	Prefrontal gating of sensory input differentiates cognitively impaired and unimpaired aging adults with HIV. <i>Brain Communications</i> , 2020, 2, fcaa080.	3.3	23
33	Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. <i>Lancet Microbe</i> , The, 2020, 1, e84-e92.	7.3	6
34	The age-related trajectory of visual attention neural function is altered in adults living with HIV: A cross-sectional MEG study. <i>EBioMedicine</i> , 2020, 61, 103065.	6.1	15
35	Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB. <i>Current HIV/AIDS Reports</i> , 2020, 17, 589-600.	3.1	5
36	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. <i>Lancet</i> , The, 2020, 396, 1994-2005.	13.7	164

#	ARTICLE	IF	CITATIONS
37	Association of Epigenetic Metrics of Biological Age With Cortical Thickness. JAMA Network Open, 2020, 3, e2015428.	5.9	18
38	Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 498-506.	2.1	78
39	Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. AIDS and Behavior, 2020, 24, 3473-3481.	2.7	27
40	“I feel empowered” women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain. Culture, Health and Sexuality, 2020, 23, 1-13.	1.8	8
41	Incidental Findings on Brain MRI in People with HIV Infection. Scientific Reports, 2020, 10, 9474.	3.3	4
42	Time to Study Immune Checkpoint Inhibitors in Patients With HIV Infection and Cancer. JCO Oncology Practice, 2020, 16, 327-328.	2.9	2
43	Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. New England Journal of Medicine, 2020, 382, 1112-1123.	27.0	266
44	Latent Tuberculosis and HIV Infection. Current Infectious Disease Reports, 2020, 22, 1.	3.0	11
45	Response to Dong et al.. Open Forum Infectious Diseases, 2020, 7, ofaa032.	0.9	0
46	High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary Clinical Trials, 2020, 90, 105938.	1.8	36
47	Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1416-1424.	5.6	42
48	Age-related visual dynamics in HIV-infected adults with cognitive impairment. Neurology: Neuroimmunology and Neuroinflammation, 2020, 7, .	6.0	20
49	Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States. Open Forum Infectious Diseases, 2019, 6, .	0.9	56
50	US Human Immunodeficiency Virus (HIV) Practitioners’ Recommendations Regarding Condomless Sex in the Era of HIV Pre-Exposure Prophylaxis and Treatment as Prevention. Open Forum Infectious Diseases, 2019, 6, ofz082.	0.9	5
51	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. New England Journal of Medicine, 2019, 380, 1001-1011.	27.0	239
52	Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Current Opinion in HIV and AIDS, 2019, 14, 13-20.	3.8	28
53	1256. Contemporary Evaluation of Racial/Ethnic Disparities in Survival and Disease Progression among People with HIV in the US Midwest. Open Forum Infectious Diseases, 2019, 6, S451-S452.	0.9	0
54	2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences. Open Forum Infectious Diseases, 2019, 6, S866-S866.	0.9	2

#	ARTICLE	IF	CITATIONS
55	368. Incidental Findings on Brain MRI in People Living with HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, S193-S193.	0.9	0
56	Interest of Youth Living With HIV in Long-Acting Antiretrovirals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 190-197.	2.1	48
57	883. Evidence from a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans Results in Viral Suppression. <i>Open Forum Infectious Diseases</i> , 2019, 6, S19-S20.	0.9	0
58	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	5.6	20
59	Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. <i>Aids</i> , 2018, 32, 761-765.	2.2	61
60	Determinants of facilitated health insurance enrollment for patients with HIV disease, and impact of insurance enrollment on targeted health outcomes. <i>BMC Infectious Diseases</i> , 2018, 18, 132.	2.9	16
61	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	4.7	108
62	1294. Acceptability and Feasibility of a Pharmacist-led Pre-exposure Prophylaxis Program in the Midwestern United States. <i>Open Forum Infectious Diseases</i> , 2018, 5, S395-S395.	0.9	1
63	Midwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. <i>PLoS ONE</i> , 2018, 13, e0207372.	2.5	20
64	Neural dynamics of selective attention deficits in HIV-associated neurocognitive disorder. <i>Neurology</i> , 2018, 91, e1860-e1869.	1.1	48
65	A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction. <i>BMC Infectious Diseases</i> , 2018, 18, 310.	2.9	2
66	Aberrant occipital dynamics differentiate HIV-infected patients with and without cognitive impairment. <i>Brain</i> , 2018, 141, 1678-1690.	7.6	69
67	Aberrant oscillatory dynamics during somatosensory processing in HIV-infected adults. <i>NeuroImage: Clinical</i> , 2018, 20, 85-91.	2.7	43
68	New and Noteworthy in Tuberculosis Diagnostics and Treatment. <i>Topics in Antiviral Medicine</i> , 2018, 26, 58-61.	0.1	3
69	Aberrant Neuronal Dynamics during Working Memory Operations in the Aging HIV-Infected Brain. <i>Scientific Reports</i> , 2017, 7, 41568.	3.3	39
70	Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 200-204.	3.0	8
71	Current strategies to treat tuberculosis. <i>F1000Research</i> , 2016, 5, 2579.	1.6	9
72	A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. <i>BMC Infectious Diseases</i> , 2016, 16, 269.	2.9	9

#	ARTICLE	IF	CITATIONS
73	Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA. <i>Molecular Cell</i> , 2016, 62, 157-168.	9.7	233
74	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 830-839.	27.0	1,282
75	Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. <i>Clinical Infectious Diseases</i> , 2016, 62, 1081-1088.	5.8	68
76	Dolutegravir-induced colitis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 281-282.	3.0	5
77	Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults. <i>Human Brain Mapping</i> , 2015, 36, 897-910.	3.6	60
78	HIV-Infected Patient Knowledge, Attitudes, and Beliefs Regarding the Affordable Care Act. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 581-586.	1.1	8
79	Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. <i>Clinical Infectious Diseases</i> , 2015, 61, 1322-1327.	5.8	63
80	Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. <i>BMC Infectious Diseases</i> , 2015, 15, 12.	2.9	15
81	Baseline Natural Killer and T Cell Populations Correlation with Virologic Outcome after Regimen Simplification to Atazanavir/Ritonavir Alone (ACTG 5201). <i>PLoS ONE</i> , 2014, 9, e95524.	2.5	2
82	1545 Knowledge, Attitudes and Beliefs Regarding the Potential Impact of Health Care Reform on HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S411-S411.	0.9	0
83	1557 Impact of HIV Pharmacist Reconciliation on Correction of Antiretroviral Prescription Errors Among Hospitalized HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S414-S414.	0.9	0
84	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2014, 14, 281-290.	9.1	423
85	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. <i>Clinical Infectious Diseases</i> , 2014, 58, 555-563.	5.8	30
86	Antiretroviral medication prescribing errors are common with hospitalization of HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 262-267.	3.0	25
87	Inactivation and viral load quantitation of human immunodeficiency virus in blood collected into Cyto-Chex® BCT blood collection device. <i>Journal of Virological Methods</i> , 2014, 196, 50-55.	2.1	5
88	Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1052-1059.	3.9	42
89	Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 423-428.	2.1	73
90	Functional Brain Abnormalities During Finger-Tapping in HIV-Infected Older Adults: A Magnetoencephalography Study. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 965-974.	4.1	58

#	ARTICLE	IF	CITATIONS
91	Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 586-593.	5.8	61
92	Decreased MEG beta oscillations in HIV-infected older adults during the resting state. <i>Journal of NeuroVirology</i> , 2013, 19, 586-594.	2.1	30
93	Pilot Study of Younger and Older HIV-Infected Adults Using Traditional and Novel Functional Assessments. <i>HIV Clinical Trials</i> , 2013, 14, 165-174.	2.0	16
94	Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. <i>Nanomedicine</i> , 2013, 8, 1807-1813.	3.3	85
95	Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 532-539.	1.2	37
96	Abnormal MEG Oscillatory Activity during Visual Processing in the Prefrontal Cortices and Frontal Eye-Fields of the Aging HIV Brain. <i>PLoS ONE</i> , 2013, 8, e66241.	2.5	29
97	Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 455-462.	2.1	71
98	Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15001-15005.	7.1	33
99	Missed visits and decline in CD4 cell count among HIV-infected patients: a mixed method study. <i>International Journal of Infectious Diseases</i> , 2012, 16, e779-e785.	3.3	19
100	New drugs to treat tuberculosis. <i>F1000 Medicine Reports</i> , 2012, 4, 12.	2.9	13
101	Pharmacodynamic and Antiretroviral Activities of Combination Nanoformulated Antiretrovirals in HIV-1-Infected Human Peripheral Blood Lymphocyte-Reconstituted Mice. <i>Journal of Infectious Diseases</i> , 2012, 206, 1577-1588.	4.0	62
102	The Effect of HIV Protease Inhibitors on Amyloid- $\beta^2$ Peptide Degradation and Synthesis in Human Cells and Alzheimer's Disease Animal Model. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 412-423.	4.1	26
103	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 493-505.	27.0	6,046
104	Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis. <i>HIV Clinical Trials</i> , 2011, 12, 79-88.	2.0	8
105	Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. <i>New England Journal of Medicine</i> , 2011, 365, 1482-1491.	27.0	491
106	The Critical Need for Alternative Antiretroviral Formulations, and Obstacles to Their Development. <i>Journal of Infectious Diseases</i> , 2011, 204, 669-674.	4.0	46
107	Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 972-979.	5.6	52
108	Clinical Evaluation of a Dried Blood Spot Assay for Atazanavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4124-4128.	3.2	10



#	ARTICLE	IF	CITATIONS
109	Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48-Week Clinical and Virologic Outcomes. <i>Journal of Infectious Diseases</i> , 2009, 199, 866-871.	4.0	52
110	Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. <i>Antiviral Therapy</i> , 2009, 14, 1-12.	1.0	16
111	Simplification Strategies to Reduce Antiretroviral drug Exposure: Progress and Prospects. <i>Antiviral Therapy</i> , 2009, 14, 1-12.	1.0	50
112	Extensively Drug-resistant Tuberculosis. <i>American Journal of Medicine</i> , 2008, 121, 835-844.	1.5	29
113	Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 358, 2095-2106.	27.0	667
114	Potential Risks and Benefits of HIV Treatment Simplification: A Simulation Model of a Proposed Clinical Trial. <i>Clinical Infectious Diseases</i> , 2007, 45, 1062-1070.	5.8	28
115	Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. <i>Aids</i> , 2007, 21, 2473-2482.	2.2	134
116	Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 806.	7.4	77
117	HIV Education Needs Among Sudanese Immigrants and Refugees in the Midwestern United States. <i>AIDS and Behavior</i> , 2006, 10, 319-323.	2.7	36
118	Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. <i>Hepatology</i> , 2006, 44, 1110-1116.	7.3	178
119	Stabilization of white blood cells and immunologic markers for extended analysis using flow cytometry. <i>Journal of Immunological Methods</i> , 2005, 305, 107-119.	1.4	42
120	Development of a rapid autopsy program for studies of brain immunity. <i>Journal of Neuroimmunology</i> , 2005, 163, 135-144.	2.3	19
121	Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. <i>Journal of Neuroimmunology</i> , 2005, 163, 145-156.	2.3	26
122	Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. <i>BMC Infectious Diseases</i> , 2005, 5, 23.	2.9	9
123	Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management. <i>Journal of the International Association of Providers of AIDS Care</i> , 2004, 3, 86-91.	1.2	39
124	Regional patterns of brain metabolites in AIDS dementia complex. <i>NeuroImage</i> , 2004, 23, 928-935.	4.2	87
125	Predictive Value of HIV-1 Viral Load on Risk for Opportunistic Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 154-158.	2.1	29
126	Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection. <i>Aids</i> , 2002, 16, 1832-1834.	2.2	28



#	ARTICLE	IF	CITATIONS
127	HIV-1-associated dementia: a basic science and clinical perspective. <i>Aids Reader</i> , 2002, 12, 358-68.	0.3	34
128	The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. <i>Journal of Neuroimmunology</i> , 2001, 120, 112-128.	2.3	43
129	Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. <i>International Journal of STD and AIDS</i> , 2001, 12, 463-468.	1.1	37
130	Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. <i>Annals of Internal Medicine</i> , 2000, 133, 21.	3.9	2,712
131	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START) Tj ETQq1 1 0z. 24314 rgBT /Over	2.4	14
132	Adherence of Human Immunodeficiency Virus-Infected Patients to Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1999, 29, 824-830.	5.8	241
133	Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. <i>American Journal of Medicine</i> , 1999, 107, 624-626.	1.5	62
134	Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. <i>International Journal of STD and AIDS</i> , 1999, 10, 383-391.	1.1	123
135	Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. <i>Aids</i> , 1999, 13, 1035-1044.	2.2	48
136	Increased Plasma Human Immunodeficiency Virus Type 1 Burden following Antigenic Challenge with Pneumococcal Vaccine. <i>Journal of Infectious Diseases</i> , 1996, 174, 1191-1199.	4.0	168
137	Prospective Utility of Cerebral Proton Magnetic Resonance Spectroscopy in Monitoring HIV Infection and Its Associated Neurological Impairment. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 977-982.	1.1	60
138	Oral histoplasmosis in a patient infected with HIV. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1994, 77, 126-130.	0.6	29
139	Primary Care Physicians and the Cost of Drugs: A Study of Prescribing Practices Based on Recognition and Information Sources. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 1159-1163.	2.0	27
140	Fluconazole-Resistant <i>Candida albicans</i> . <i>Clinical Infectious Diseases</i> , 1993, 17, 1018-1021.	5.8	164
141	The Value of a Longitudinal HIV Track for Medical Students: Ten-Year Program Evaluation. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	0
142	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.0	3